NCT04661033 - Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

June 26, 2023

Study Completion Date

June 26, 2023

Conditions

Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions

DRUG

Isatuximab SAR650984

Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Trial Locations (6)

Fox Chase Cancer Center Site Number : 8400004, Philadelphia

Investigational Site Number : 3800001, Milan

Investigational Site Number : 2760001, Essen

Investigational Site Number : 2500001, Créteil

Investigational Site Number : 5280001, Leiden

Investigational Site Number : 8260001, London